---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-002321"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2022-01-25T23:59:59+00:00"
generated_at: "2026-06-27T15:54:09.931414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics amends supply agreement with EirGenix for trastuzumab biosimilar; up to $2M milestones

## Summary
- Amended supply agreement with EirGenix for bulk drug substance EG12014, a trastuzumab biosimilar used in BDC-1001 HER2 Boltbody ISAC.
- Requires joint steering committee, revised forecasting/order terms, and pricing adjustments based on production scale.
- Company to make up to $2.0M in milestone payments upon regulatory achievements for HER2 Boltbody ISAC.
- Agreement remains effective as long as Bolt or affiliates continue development/commercialization of the ISAC product.

## SEC filing metadata
- accession: 0001564590-22-002321
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2022-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000156459022002321/0001564590-22-002321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000156459022002321/bolt-8k_20220125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-002321
- JSON: https://secwatch.observer/filing/0001564590-22-002321.json
- Plain text: https://secwatch.observer/filing/0001564590-22-002321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.